Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Carbiotix completes expansion of research and development laboratory

Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has completed the expansion of its research and development laboratory in Lund, Sweden. The expansion of a third laboratory will provide us separate laboratories for LinkGut sample analysis, microbial therapeutic research, and prebiotic ingredient development. The laboratory expansion will also provide additional office space that will allow the Company to bring together all personnel based in Lund into one office and laboratory area. The expansion allows Carbiotix to ramp up research and development activities

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 25th April 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,755,037 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Realheart to recruit new CFO

Press release 26 April, 2022 Realheart has initiated the process of recruiting a new Chief Financial Officer to take over when current CFO Andreas Hultdin leaves on 31 July.Realheart is a Swedish company headquartered in Västerås, which is developing the world's first artificial four-chamber heart. The company has recently taken several important steps forward, not least in leaving the prototype behind and instead test the clinical version of the Realheart TAH in the animal studies that are about to be initiated. ''As we step by step move closer the clinical trial phase, we see

Interim report January–March 2022 – Pricer AB (publ)

High order intake of 24.4% and net sales growth of 18.6 %   Q1 2022   · Net sales amounted to SEK 465.9 M (392.9) an increase of 18.6 percent compared to the same period last year. · Operating profit amounted to SEK -9.7 M (17.3), which corresponds to an operating margin of -2.1 percent (4.4). · Order intake was 551 MSEK (443), an increase of 24,4 percent compared to the same period last year. · Order backlog amounted to SEK 464 M (550), of which the majority is expected to be delivered in Q2 and Q3 2022. · Profit for the period was SEK -9.5 M (17.7). · Earnings

Genova has entered into new financing agreements of approximately SEK 3,200m

Genova Property Group AB (publ) has entered into new financing agreements with Swedbank AB (publ) for a total of SEK 3,200m, of which SEK 350m consists of a revolving credit facility. The new facilities relate to Genova's existing investment property portfolio and comprise a total of 43 properties. The refinancing also strengthens Genova's liquidity by almost SEK 170m. The new financing agreements will mature in May 2027, with an average maturity of approximately 4 years. The new financing agreements are based on Genova's green framework and can be converted to green financing when

Invitation – presentation of Cary Group’s report of the first quarter 2022

Cary Group will publish its first quarter results on Tuesday, May 10, 2022 at approximately 08:00 AM CET. A conference call for investors, analysts and financial media will be held at 10:00 AM CET.The report will be presented by Anders Jensen, CEO, as well as by Joakim Rasiwala, CFO. The telephone conference will be webcasted live at www.carygroup.com where presentation material will be available as soon as the report is released. Dial-in details for the conference call: SE: +46 8 566 42 705UK: +44 333 300 92 67US: +1 6 319 131 422 PIN US: 91572095# For more information,

Gasum obtains LNG distribution license in Belgium

The Nordic energy company Gasum has obtained a distribution license for liquified natural gas (LNG) on the Belgian market. The distribution license allows Gasum to expand its supply network and guarantees safe and high-quality deliveries of LNG to customers bunkering in Belgium.Gasum expands the outreach and quality of its maritime LNG offering and further improve the service to its shipping customers. As part of this strategy, Gasum has now obtained a license to deliver LNG for maritime customers in Belgium. The new LNG distribution license obtained on March 17, 2022, will allow Gasum

TePe publishes its 2021 Sustainability Report

Oral care company TePe Oral Hygiene Products AB has now published its annual Sustainability Report, highlighting progress and improvements of 2021. The report is available at www.tepe.com.“At TePe, we want to contribute to positive change and continue creating value for our customers and consumers. Besides promoting health and wellbeing, our teams have put tremendous efforts into reducing the carbon footprint of our products and packaging by means of continuous improvements, shifting to renewable sources, and using green energy”, says Hanna Hageberg Hammar, CEO of TePe.  Selected

Pilloxa provides digital patient support solution for Type 1 Diabetes/Addison’s Disease trial at Sahlgrenska University Hospital

Stockholm, Sweden, April 26, 2022: Digital health company Pilloxa today announced they have signed a collaboration to provide a digital patient support solution based on their software and smart pillbox for a trial to be conducted at Sahlgrenska University Hospital involving patients with Type 1 Diabetes and Addison’s Disease. The project involves the Department of Endocrinology-Diabetes-Metabolism at Sahlgrenska University Hospital as well as the Department of Internal Medicine and Clinical Nutrition at the Institute of Medicine at Sahlgrenska Academy within the University of Gothenburg.

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

First quarter (January-March 2022) · Operating profit/loss totaled SEK -4,741,051 (-2,404,551). · Loss for the period totaled SEK -4,754,615 (-2,404,489). · Cash flow from operating activities totaled SEK -5,333,226 (-3,481,034). · Earnings per share before dilution totaled SEK -0.24 (-0.20) Earnings per share after dilution amounted to SEK -0.24 (-0.20).   Key events during the first quarter · Elicera Therapeutics boosted IP protection for ELC-100 through the acquisition of patents from Immunicum. · Elicera Therapeutics secured SEK 5 million in grant financing

Metso Outotec introduces a comprehensive Tailings Management Solutions portfolio

Metso Outotec Corporation’s press release on April 26, 2022, at 09:00 a.m. EESTMetso Outotec is introducing its comprehensive Tailings Management Solutions offering for the sustainable management of mine tailings. The offering unites the company’s frontrunning products with decades of process expertise and covers tailings thickening and dewatering as well as handling through conveying and dry stacking. In addition, Metso Outotec offers a frontrunning portfolio of solutions for the treatment of water produced during dewatering, enabling closed water loops while managing the level of

AcuCort applies for ethical review for a questionnaire study on allergy treatment

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces today that the company has submitted an ethical review application to the Swedish Ethical Review Authority regarding a questionnaire study. The purpose of the study is to document how allergy patients value their treatment. The questionnaire study is an important part of the future pricing and reimbursement application to the Swedish Dental and Pharmaceutical Benefits Agency, TLV.ISICORT® is a thin, small fast-dissolving oral film that is placed on the tongue where the active anti-inflammatory substance, dexamethasone, dissolves

Getinge Interim Report January-March 2022: Healthy order book but supply chain challenges

“Net sales declined by 6.4% and the order intake fell organically by 4.4% in the quarter,” says Mattias Perjos, President & CEO. ”However, excluding the strong sales of ventilators in 2021, we had organic growth in both order intake and net sales. The order book grew 8% during the quarter and is 21% higher now than the same period in 2021, excluding currency fluctuations”.Getinge has a strong pipeline of orders and the sales forecast for the full-year remains unchanged. The deliveries were negatively affected toward the end of the quarter as a result of temporary supply chain challenges.

BoMill publishes information memorandum regarding the Rights Issue

BoMill AB (publ) (”BoMill” or the “Company”) today publishes an information memorandum by reason of the proposed preferential rights issue of shares resolved by the Extraordinary General Meeting of BoMill on April 8,  2022. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 23.3 million before issue costs. The Rights Issue is secured through underwriting commitments corresponding to 100 percent of the maximum issue volume.Information memorandum and application form The information memorandum for the issue has been published on BoMill’s website (www.

Dividend Payment

26 April 2022 Gulf Keystone Petroleum Ltd. (LSE: GKP) ("Gulf Keystone", "GKP" or "the Company") Dividend Payment On announcing Gulf Keystone's 2021 Full Year Results on 30 March 2022, the Company declared an interim dividend of $65 million. The payment is equivalent to 30.313 US cents per Common Share of the Company. It has been converted into pounds sterling at a rate of $1:£0.7844 prevailing on 25 April 2022, and hence a dividend of 23.778p per Common Share will be paid on 13 May 2022 to those shareholders on the register of members of the Company as at 29 April 2022.

ABGSC – Q1 2022 Interim Report

Highlights: · Q1 revenues of NOK 487m (NOK 738m) in turbulent markets · 2022 Q1 diluted EPS of NOK 0.17 (NOK 0.39) · Pipeline remaining at solid levels CEO comment:I am very pleased to again report a solid quarter with revenues just shy of the NOK 500m mark. Although revenues are down compared to the outstanding Q1 last year, the first quarter is normally seasonally slow, and this year’s performance is particularly strong in a historical context. The year got off to a good start, with market activity remaining high in the first half of the quarter, until we sadly again

Invitation – presentation of first-quarter results

KlaraBo will publish its interim report for the first quarter of 2022 at 8:00 a.m. (CEST) on Tuesday, 3 May, and will hold a webcast presentation and teleconference at 09:00 a.m. (CEST) the same day. KlaraBo’s CEO Andreas Morfiadakis and CFO Jenny Appenrodt will present the interim report and respond to questions. The presentation will be held in English. TeleconferenceTime: 09:00 a.m. (CEST) on Tuesday, 3 May 2022To participate in the teleconference, call: +46 8 505 583 58 Webcast presentationLink to webcast: https://tv.streamfabriken.com/klarabo-q1-2022The presentation and

Interim Report, January - March 2022

Strong growth within both systems and servicesJanuary – March 2022 · Revenues increased by 19 per cent to SEK 1,065 million (894).  · Adjusted EBITA increased by 26 per cent and amounted to SEK 52.5 million (41.6), corresponding to an adjusted EBITA margin of 4.9 per cent (4.7).  · Profit before tax amounted to SEK 37.5 million (30.8).  · Profit after tax amounted to SEK 33.9 million (22.5).  · Profit per share amounted to SEK 1.24 (0.82).  · New contracts relating to cloud services worth SEK 122 million (78) were contracted, an increase by 56 per cent.  ·

Loudspring Oyj: Q1 2022 Summary

Loudspring Oyj Company release 26th April 2022 at 9:00 (EET) Please note that this report is not a fully comprehensive report of all events, nor is it in any way a financial performance report. It is only a summary of the main events that have affected us and our portfolio during the quarter and before the date of this report where separately indicated below. In the quarterly report we will not comment on every portfolio company but focus on our core holdings. To get a comprehensive overview of individual portfolio companies’ businesses one should review additional documents

Kindred’s revenue from harmful gambling decreased to 3.3 per cent in the first quarter of 2022

In the first quarter of 2022, Kindred’s share of revenue from harmful gambling decreased to 3.3 per cent. Increased focus on improving and optimising intervention measures has contributed to the decrease. Kindred also entered a collaboration with RecoverMe, an app supporting users regain control of their gambling habits.In the first quarter of 2022, Kindred Group plc’s (Kindred) share of revenue from harmful gambling decreased to 3.3 (3.9) per cent. The positive trend has been impacted by seasonal changes, with the first quarter historically seeing lower shares of revenue from harmful

Axel Johnson launches fintech startup Humla using SEB’s Banking-as-a-Service platform

SEB is entering into a strategic partnership with Humla, a fintech startup within Axel Johnson set out to drive innovation in the retail industry. Humla will develop its products and offerings on the banking-as-a-service (BaaS) platform developed by SEBx, thereby becoming its first BaaS customer. The partnership follows a period of joint exploration and collaboration between Humla and SEB’s innovation studio SEBx. Humla is on a mission to strengthen the business for the retail of tomorrow by building a new generation of financial services and loyalty products. Using SEBx’s banking-as-a-

Elos Medtech Interim Report January 1 - March 31, 2022

January – March 2022 · Net sales for the first quarter amounted to SEK 194.5 (171.2) million, an increase of 13.6 percent compared to the same quarter last year. Net sales in local currencies increased by 7.6 percent. · Operating profit amounted to SEK 29.2 (25.0) million, corresponding to an operating margin of 15.0 (14.6) percent. · Profit after net financial items amounted to SEK 29.8 (27.1) million. Net financial items were positively affected by exchange rate differences of SEK 0.8 (2.8) million and totaled SEK 0.6 (2.1) million. · Profit after tax amounted to SEK 23.0 (

Q1 2022: Order pattern in Americas gave a weaker start to the year

Important events during the first quarter · Net sales decreased by 10% (-16% adjusted for currency effects) to SEK 155 m (171). · The EBITDA margin was 25% (28). · The Americas were affected by customers' order patterns, which contributed to a weaker quarter. EMEA and APAC on par with the previous year adjusted for milestone-related revenue. · Important step in the technological transfer of Blis products with the first commercial production batch of BLIS K12. · New laboratory completed in Lund with the aim of improving pre-clinical ability and providing increased

There are no items matching the current filter
There are no more items matching the current filter
Back to top